Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb/III Trial of Allocetra for the Treatment of Organ Dysfunction Associated with Sepsis

Trial Profile

A Phase IIb/III Trial of Allocetra for the Treatment of Organ Dysfunction Associated with Sepsis

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 07 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
  • Indications Immunological disorders; Sepsis
  • Focus Therapeutic Use
  • Sponsors Enlivex Therapeutics
  • Most Recent Events

    • 07 May 2020 According to an Enlivex Therapeutics media release, the planned Phase IIb trial part will be a controlled, randomized study that is expected to commence in the fourth quarter of 2020.
    • 13 Apr 2020 According to Enlivex Therapeutics media release, following the positive results of Phase Ib clinical trial in severe sepsis patients, Enlivex currently plans to initiate this year a Phase IIb/III trial of Allocetra for the treatment of organ dysfunction associated with sepsis.
    • 25 Feb 2020 According to Enlivex Therapeutics media release, study is expected to start in 2020.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top